Mersana Therapeutics, Inc. (MRSN) Analysts See $-0.03 EPS

Analysts expect Mersana Therapeutics, Inc. (NASDAQ:MRSN) to report $-0.03 EPS on May, 9 before the open.They anticipate $0.51 EPS change or 94.44 % from last quarter’s $-0.54 EPS. After having $-0.97 EPS previously, Mersana Therapeutics, Inc.’s analysts see -96.91 % EPS growth. The stock increased 2.04% or $0.11 during the last trading session, reaching $5.5. About 30,204 shares traded. Mersana Therapeutics, Inc. (NASDAQ:MRSN) has declined 74.65% since May 8, 2018 and is downtrending. It has underperformed by 79.02% the S&P500.

Mersana Therapeutics, Inc. is a biotechnology firm that discovers, engineers, and develops antibody drug conjugates to cure various cancers. The company has market cap of $262.26 million. The firm develops immune conjugate therapies to create drugs that enhance patients?? lives. It currently has negative earnings. It offers XMT-1522, a drug therapy for tumor models that express relatively low amounts of the HER2 protein; and human anti-HER2 antibody used in XMT-1522.

More notable recent Mersana Therapeutics, Inc. (NASDAQ:MRSN) news were published by: which released: “Mersana Therapeutics Appoints Dirk Huebner, M.D., as Chief Medical Officer – GlobeNewswire” on November 27, 2018, also with their article: “Dow snaps 5-day win streak as financials sell off – MarketWatch” published on July 19, 2018, published: “Big Lots, Inc. (BIG) Ex-Dividend Date Scheduled for December 13, 2018 – Nasdaq” on December 12, 2018. More interesting news about Mersana Therapeutics, Inc. (NASDAQ:MRSN) were released by: and their article: “Pharmaceutical Update: Q3 2018 in Review – Investing News Network” published on October 16, 2018 as well as‘s news article titled: “Plymouth Industrial REIT, Inc. (PLYM) Ex-Dividend Date Scheduled for March 28, 2019 – Nasdaq” with publication date: March 27, 2019.

Mersana Therapeutics, Inc. (NASDAQ:MRSN) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.